biote Corp.

biote Corp. (Nasdaq: BTMD), which came public through the de-SPAC merger with Haymaker Acquisition Corp. II (ticker: HYAC), is a healthcare company focused on hormone optimization, primarily through subcutaneous pellet therapy for practitioners treating hormone deficiency. The blank-check vehicle was sponsored by Haymaker Sponsor II, LLC, a group linked to veteran consumer and healthcare investor Andrew Taub, and completed its IPO in 2021. The business combination closed in 2022, transitioning biote from a SPAC-stage entity to a publicly traded operating company in the healthcare services sector. The company filed an 8-K current report with the SEC on May 18, 2026 under accession number 0001193125-26-229013. For complete filing history, transaction details, and real-time SPAC analytics on biote and hundreds of other deals, create a free account at SpacDesk.